Physical Exercise Versus Rosiglitazone in CAD and Prediabetes

Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00675740

Enrollment

Registered

2008-05-12

Start date

2004-01-31

Completion date

2007-02-28

Last updated

2010-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired Glucose Tolerance

Brief summary

The aim of this study is to prospectively assess the relative benefits of either treatment with rosiglitazone or physical exercise on endothelial function in patients with impaired fasting glucose or impaired glucose tolerance and coronary artery disease (CAD).

Interventions

DRUGrosiglitazone

tablets 4 mg daily

BEHAVIORALphysical exercise

stationary bike 5-6 times a week

OTHERcontrol

control without intervention

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

35 Years to 70 Years

Healthy volunteers

Inclusion criteria

* impaired fasting glucose or impaired glucose tolerance * angiographic evidence of coronary artery disease

Exclusion criteria

* diabetes mellitus type I or II * preexisting antidiabetic medication * unstable angina * indication for coronary bypass surgery * significant left main disease * myocardial infarction within preceding 3 months * ejection fraction \< 40% * significant heart valve disease * severe metabolic disorders * severe disorders in lipoprotein metabolism * thyroid disorders * alcohol or drug abuse * pregnancy * participation in another trial

Design outcomes

Primary

Measure	Time frame
between-group difference in flow-mediated dilation of the brachial artery	6 months

Secondary

Measure	Time frame
relative effects of treatment on parameters of - glucose metabolism - inflammatory plasma markers - markers of endothelial function - cellular markers in muscle and fat biopsies	6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026